

The Pfizer logo, featuring the word "Pfizer" in a white, serif font inside a blue oval, which is itself set within a larger white oval on a blue background.

## COVID Response

### Industry Leadership

Pfizer outlined a 5-Point Plan to combat COVID-19 in early March, calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration across the healthcare innovation ecosystem, including government and academia.

### Philanthropic Support

The Pfizer Foundation and Pfizer Inc. are providing \$40 million in medical and charitable cash grants to help address urgent needs of US and global partners on the frontlines of the pandemic. The Foundation is also matching colleague donations to local, national, and global charitable organizations.

In the United States, Pfizer has temporarily adapted some elements of the Pfizer Patient Assistance Program to accommodate the evolving needs of patients it serves and ensure they get access to their medicines without interruption. To date, upon request, Pfizer has responded by increasing patient supply during the quarantine, where possible, approved telehealth prescribing, and more.

### Applying Science

Pfizer is advancing the battle against COVID-19 on multiple fronts, working relentlessly to develop an investigational antiviral compound to treat the cause of COVID-19 infections, a vaccine to prevent infection, as well as evaluating other therapies that have scientific potential to help infected patients fight the virus.

### Coronavirus Updates

Pfizer has developed a Coronavirus Resource Page on its website, which includes educational information for the public and updates on how Pfizer is responding to the pandemic.